Corrections needed to 2016 ESC and AHA guidelines on heart failure

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 5, 2017, Pages 325-326

  Rydén, Lars ^a   Van de Werf, Frans ^b   Armstrong, Paul W ^c   McGuire, Darren K ^d   Standl, Eberhard ^e   Peterson, Eric D ^f   Holman, Rury R ^g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Munich Diabetes Research Group at the Munich Helmholtz Centre   (Germany)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; ENZYME ACTIVITY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GLYCEMIC INDEX; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INSULIN RELEASE; LETTER; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; BLOOD; CHEMICALLY INDUCED;

DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GUIDELINES AS TOPIC; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS;

EID: 85017250170     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30102-X     Document Type: Letter

References (6)

1. 1 Ponikowski, P, Voors, AA, Anker, SD, et al., for the Authors/Task Force Members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
2. 2 Nauck, M, Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
3. 3 Standl, E, Schnell, O, Darren, K, McGuire, D, Ceriello, A, Rydén, L, Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30033-5 published online Jan 25.
4. 4 FDA. Diabetes medications containing saxagliptin and alogliptin: drug safety communication—risk of heart failure. https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494252.htm (accessed March 30, 2017).
5. 5 Page, RL 2nd, O'Bryant, CL, Cheng, D, et al. American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology Council on Cardiovascular Surgery and Anesthesia Council on Cardiovascular and Stroke Nursing Council on Quality of Care and Outcomes Research Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134 (2016), e32–e69.
6. 6 McGuire, DK, Van de Werf, F, Armstrong, PW, et al., for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 126–135.